Form 4: Director Richard Marshall Increases Stake in Serina

Director Richard Peter Marshall acquired 12,183 shares of Serina Therapeutics, Inc. common stock at a weighted average price of $1.65.

Summary

• Director Richard Peter Marshall purchased 12,183 shares of Serina Therapeutics (SER) common stock.
• The transaction occurred on May 19, 2026.
• The shares were acquired at a weighted average price of $1.65 per share, with individual transaction prices ranging from $1.59 to $1.73.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as open-market purchases by directors indicate alignment with shareholder interests and confidence in the company's prospects.

Positives

• Insider confidence is demonstrated by a director purchasing shares on the open market.
• The purchase increases the director's direct beneficial ownership in the company.

Negatives

• None identified in this filing.

Risks

• Market price volatility for SER shares as indicated by the range of purchase prices ($1.59 to $1.73).

Future Outlook

Not applicable as this is a disclosure of a past transaction.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal of management's belief in the company's long-term valuation, particularly in the biotechnology sector where Serina Therapeutics operates.

Comparison to Industry Standards

• Insider purchases are standard corporate governance disclosures and align with typical market behavior for directors increasing their equity alignment with shareholders.

Stakeholder Impact

• Shareholders may perceive the director's purchase as a vote of confidence in the company's current valuation.

Key Dates

Keywords

Serina Therapeutics, SER, Insider Trading, Form 4, Director Purchase